Who Watches The Watchmen?

You know the old story. There is trouble in town. Big trouble. Everyone runs, but some, a select and special few, a legion of warriors, run towards danger to protect the rest of the community. In the human body, that select and special few are our immune cells, racing to the scene of injury, disease and dysfunction to try and restore us to health.

But there is another chapter to the old story. What if the burdens of battle become too much, and over time, the warriors grow less effective and prone to bad decision-making? This scenario isn't reserved for drama, but also happens in our bodies. What can we do when dysfunction emerges in our immune system itself? We discussed the tricky problem of autoimmunity in an earlier blog. An approach we highlighted was the use of chimeric antigen receptor T-cells (CAR-T), a treatment previously reserved for cancer.

A CAR-T treatment can train the immune system to target the cells responsible for autoimmunity, in other words, to seek out and destroy the failing aspects of itself. This therapeutic approach recently produced a remarkable result, when a patient, with a single treatment, experienced an effective cure of not one but three autoimmune conditions. According to the patient's clinician, interviewed by New Scientist, she progressed from “deathly sick and bedridden” to "perfectly fine" twenty-five days after treatment began. This complete remission remained in place after nearly a year, a result all the more notable since patient had suffered from multiple diseases: immune thrombocytopenia (ITP), antiphospholipid antibody syndrome (APLAS), and, autoimmune haemolytic anaemia (AIHA). All of those conditions had proven resistant to previous treatments.

While CAR-T remains expensive, the more we learn, the more those costs will likely reduce. Serious long-term conditions are not often curable, and fixing an autoimmune condition (or three!) must radically save costs down the line. This unfamiliar calculation can now be explored, something already well underway within blood cancers, where CAR-T arrived first. Chen et al (2026) wisely caution against overgeneralisation in this early stage. However, they observe from early cases that "remission may persist even after B-cell reconstitution", suggesting that some therapies may deliver "broader immune-network remodeling." While it is too early to know which treatments and diseases will produce good levels of durable remission, in such cases, economic calculations become even more favourable. The initial treatment, however costly, won't simply remove future medical costs associated with the treated conditions, but, by restoring a functioning immune response, the patient is less dependent upon future medical intervention. To indulge in my guilty pleasure of metaphor mixing, we might both restore a patient's ability to fish alongside re-teaching their inner physician to heal themselves. And there can’t be much wrong with doing that…